Cognitive Dysfunction
3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
HM
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Huadong MedicineGulingji capsules
KynexisKYN-5356
Alliance Pharmaceuticalsiomazenil
Eli Lilly and CompanyRetinal scan
Clinical Trials (4)
Total enrollment: 223 patients across 4 trials
Guilingji Capsule for Mild-to-moderate Cognitive Impairment
Start: Aug 2018Est. completion: Dec 2019
Phase 2Unknown
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
Start: Dec 2023Est. completion: Oct 2024
Phase 1Completed
GABA-glutamate Interactions and Psychosis
Start: Jan 2007Est. completion: Oct 201823 patients
Phase 1Completed
A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
Start: Dec 2025Est. completion: Aug 2026200 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space